Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341733 | 0.74 | HSP90AA1 (0.38) | KDM4ETDP1HSP90AA1HSP90AB1CCR9 | |
| SCHEMBL24943810 | 0.70 | CCR9 (0.37) | KDM4ETDP1HSP90AA1HSP90AB1CCR9 | |
| SCHEMBL24944395 | 0.68 | HSP90AA1 (0.36) | KDM4ETDP1HSP90AA1HSP90AB1CCR9 | |
| SCHEMBL8957563 | 0.64 | NOTUM (0.54) | KDM4ETDP1HSP90AA1HSP90AB1CCR9 | |
| SCHEMBL27790682 | 0.61 | POLB (0.66) | KDM4E | |
| SCHEMBL20959828 | 0.61 | TSHR (0.39) | KDM4ETDP1 | |
| SCHEMBL16418638 | 0.60 | MCL1 (0.58) | KDM4ECCR9 | |
| SCHEMBL14006351 | 0.58 | MCL1 (0.41) | KDM4ETDP1CCR9 | |
| SCHEMBL28678798 | 0.57 | MCL1 (0.41) | KDM4ETDP1CCR9 | |
| SCHEMBL20618778 | 0.56 | KCNH2 (0.41) | TDP1CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | KDM4E 3164/4885TDP1 2001/4885HSP90AA1 522/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KDM4E 2224/4885TDP1 2007/4885HSP90AA1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.